Innovent Biologics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	13,042	9,422	6,206	4,556	4,270
Revenue	13,042	9,422	6,206	4,556	4,270
Revenue Growth (YoY)	38.42%	51.82%	36.21%	6.71%	11.08%
Cost of Revenue	3,075	2,412	1,807	1,382	1,224
Gross Profit	9,966	7,010	4,399	3,175	3,045
Selling, General & Admin	6,640	5,085	3,851	3,426	3,426
Research & Development	2,624	2,202	2,112	2,871	2,323
Operating Expenses	9,264	7,287	5,963	6,297	5,749
Operating Income	702.11	-276.57	-1,564	-3,123	-2,703
Interest Expense	-79.6	-67.65	-98.62	-101.7	-62.46
Interest & Investment Income	438.69	423.45	452.84	189.54	151.76
Earnings From Equity Investments	-96.79	-41.01	-	-	-
Currency Exchange Gain (Loss)	-246.83	130.28	60.82	752.05	-198.75
Other Non Operating Income (Expenses)	117.36	76.13	90	107.32	46.78
EBT Excluding Unusual Items	834.94	244.64	-1,059	-2,176	-2,766
Gain (Loss) on Sale of Investments	4.56	179.03	30.81	5.1	125.02
Gain (Loss) on Sale of Assets	-0.57	-22.99	-0.95	0.06	-0.71
Asset Writedown	-	-479.3	-115.36	-	-
Pretax Income	838.92	-78.62	-1,144	-2,170	-2,642
Income Tax Expense	25.36	16.01	-116.5	8.8	87.04
Earnings From Continuing Operations	813.57	-94.63	-1,028	-2,179	-2,729
Net Income	813.57	-94.63	-1,028	-2,179	-2,729
Net Income to Common	813.57	-94.63	-1,028	-2,179	-2,729
Shares Outstanding (Basic)	1,677	1,627	1,560	1,490	1,456
Shares Outstanding (Diluted)	1,741	1,627	1,560	1,490	1,456
Shares Change (YoY)	6.98%	4.35%	4.67%	2.37%	7.27%
EPS (Basic)	0.48	-0.06	-0.66	-1.46	-1.87
EPS (Diluted)	0.47	-0.06	-0.66	-1.46	-1.88
Free Cash Flow	-	321.36	-971.58	-2,816	-3,090
Free Cash Flow Per Share	-	0.20	-0.62	-1.89	-2.12
Gross Margin	76.42%	74.40%	70.89%	69.67%	71.32%
Operating Margin	5.38%	-2.94%	-25.20%	-68.54%	-63.31%
Profit Margin	6.24%	-1.00%	-16.56%	-47.83%	-63.91%
Free Cash Flow Margin	-	3.41%	-15.65%	-61.80%	-72.38%
EBITDA	1,003	23.99	-1,288	-2,878	-2,538
EBITDA Margin	7.69%	0.26%	-20.76%	-63.16%	-59.44%
D&A For EBITDA	300.56	300.56	275.6	245.09	165.4
EBIT	702.11	-276.57	-1,564	-3,123	-2,703
EBIT Margin	5.38%	-2.94%	-25.20%	-68.54%	-63.31%
Effective Tax Rate	3.02%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.